Fact sheet as of 30 June 2012 - Carnegie Asset Management

fettlepluckyBiotechnology

Dec 1, 2012 (4 years and 10 months ago)

225 views

Carnegie Biotechnology
Security code (ISIN):LU0119485372
Launch date:8 November 2000
Management fee:1.10% per annum*
Dealing:Monthly
Investment Manager:Carnegie Asset Management
Portfolio Manager:Ulf Arvidsson
Base currency:EUR
Price:13.80
Size:17.78 million
Minimum investment:EUR 1,000
Benchmark:Nasdaq Biotechnology
Fact sheet as of 30 June 2012
*There is a performance fee of 20% of the increase in the NAV, when performance exceeds 5% per annum.
The Carnegie Biotechnology Fund is an unincorporated open-ended collective investment fund registered in
Luxembourg under Part II of the Law of December 20, 2002 and does not qualify as an undertaking for
collective investment in transferable securities (“UCITS”), as the fund shall raise capital without promoting the
sale of the units to the public within the European Union.
Investment Returns
Top 10 holdings Share in %
Alexion Pharmaceuticals 8.2
Biomarin Pharma 7.2
Gilead Sciences 6.8
Regeneron Pharmaceuticals 6.7
Celgene 6.1
Biogen Idec 5.4
Onyx Pharmaceuticals 5.2
Immunogen 4.7
Salix Pharmaceuticals 3.7
Auxilium Pharmaceuticals Inc 3.6
Return in % Last month YTD 1 Year 3 Years 5 Years 10 Years Lifetime P.a.
Portfolio 6.0 31.3 45.0 106.0 52.5 208.7 38.0 2.8
Benchmark 2.5 27.0 37.8 97.5 76.3 104.5 -29.1 -2.9
Relative performance 3.5 4.3 7.2 8.5 -23.8 104.2 67.1 5.7
Risk Measures 3 Years 5 Years 10 Years Lifetime P.a.
Std. dev. portfolio 15.3 17.5 21.0 25.0 25.0
Std. dev. benchmark 14.7 17.7 19.6 26.0 26.0
Tracking error 4.5 6.6 11.8 13.0 -
Beta 1.0 0.9 0.9 0.8 -
We must emphasize that the figures in this publication are historical, and that past returns cannot be used as a
reliable indicator of future returns.
Front page / Funds / Carnegie Biotechnology / Fact Sheet
Sector Exposure
Geographic Diversification
The fund's investment objective is to seek capital growth by investing in equities in the biotechnology/bioscience
area, including companies with activities in the areas of drug delivery, drug discovery, therapeutics, enabling
technologies and diagnostics. Biotech is a research-intensive sector currently in an era of new discoveries and
scientific progress. The strategy invests primarily in fast-growing smaller research and pharma companies,
which are underanalyzed compared to the bigger ones and consequently more difficult to value. Patent
expirations among the bigger companies drives demand. Expiring patents lead to shrinking profits and in order
to compensate for this, new products are needed. Smaller biotech companies with drugs under development
benefit from this, and the number of new drugs under development is steadily increasing. The fund may be
leveraged up to 25 per cent of the value of its net assets for investment purposes.